Motoneurone Disease Stroke Peripheral Neuropathy Multiple Sclerosis Lennox-Gastaut
Drug Platform Publications Collaborations
Our Mission Management Team Advisory Boards
Press Releases

Fast Forward Funding

CuroNZ is delighted to achieve the support of Fast Forward for its Multiple Sclerosis (MS) preclinical drug programme,  CuroNZ founder,  Dr Frank Sieg, said it was welcome confirmation of the company’s work targeting the progressive forms of the (currently untreatable) disease.

“This is a particularly pleasing as Fast Forward only supports a small number of projects globally each year. It will allow us to continue development of a drug candidate with outstanding potential to treat MS sufferers.”

CuroNZ is the first New Zealand company to be funded at the preclinical stage of development and also the first to be funded from Fast Forward’s General fund.

“With its unique mechanism of action and a pristine safety profile, NRP2945 has outstanding potential to eventually be developed into a product that can help MS sufferers worldwide.  With the Fast Forward funds CuroNZ will reach a major inflection point in 2014 with significant benchmark valuations ahead,” Dr Sieg said.

CuroNZ is a small Biotechnology start-up company with a drug patent portfolio covering the peptide family, Neural Regeneration Peptides (NRPs), which were discovered by one of CuroNZ's Directors, Dr Frank Sieg.

Our plan is to  develop our drug to the end of preclinical and Phase I Clinical development with the aim of licensing it or reaching other commercial arrangements to enable our partners  to take it to market.

Business Overview

  • Patent claims directed to neural regeneration and protection regarding the central nervous system
  • In excess of NZ $7 million invested in the development of these compounds to date
  • Lead compound in mid to late phase of preclinical development
  • Unique mechanism of action which produces both regeneration of CNS tissue and anti-inflammatory effects
  • Support from the General Fast Forward fund to develop NRPs for progressive MS

These exciting peptides have proven efficacy within various animal disease models indicating significant future therapeutic effects for several human central neural system diseases which currently have few treatments and potentially other applications. 

Our drug has huge potential, however, we need additional investment to enable us to achieve our technical and commercial goals.

Go To:

Contact Us About Us Research Target Diseases Investors